

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	
				Filing Date	Even Date Herewith
				First Named Inventor	David WALLACH
				Group Art Unit	11633
				Examiner Name	RIGGS
				Attorney Docket Number	WALLACH=27A
Sheet	1	of	3		

[illegible][illegible]

Examiner Signature		Date Considered	7/5/06
--------------------	---	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 3

Complete if Known

Application Number	
Filing Date	Even Date Herewith
First Named Inventor	David WALLCH
Group Art Unit	1633
Examiner Name	RIGGINS
Attorney Docket Number	WALLACH=27A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PKR		Anderson, WF, "Human Gene Therapy", <u>Nature</u> 392:25-30 (1998).	
		Didonato, J.A. et al, "A Cytokine-responsive IκB Kinase that Activates the Transcription Factor NF-κB", <u>Nature</u> 388:548-554 (1997)	
		Kmiec, EB., "Gene Therapy", <u>American Scientist</u> 87:240-247	
		Li et al, "Interaction of an Adenovirus E3 14.7 - Kilodalton Protein with a Novel Tumor Necrosis Factor Alpha-Inducible Cellular Protein Containing Leucine Zipper Domains", <u>Molecular and Cellular Biology</u> 18:1601-1610 (1998)	
		Li et al, "Identification of a Cell Protein (FIP-3) as a Modulator of NF-κB Activity and as a Target of an Adenovirus Inhibitor of Tumor Necrosis Factor α-induced Apoptosis", <u>Proc. Natl. Acad. Sci. USA</u> 96:1042-1047	
		Malinin, N.L. et al, "MAP3K-related Kinase Involved in NF-κB Induction by TNF, CD95 and IL-1", <u>Nature</u> 385:540-544 (1997)	
		Mountain, A., "Gene Therapy: The First Decade", <u>Trends in Biotechnology</u> 18:119-128 (2000)	
		Nagase, T. et al, "Prediction of the Coding Sequences of Unidentified Human Genes, XII. The Complete Sequence of 100 New cDNA Clones from Brain Which Code for Large Proteins in Vitro", <u>DNA Res</u> 5: 355-364 (1998)	
		Rothwarf, D.M. et al, "IKK-gamma is an Essential Regulatory Subunit of the IκB Kinase Complex", <u>Nature</u> 395:297-300 (1998)	
		Song, H.Y. et al, "Tumor Necrosis Factor (TNF)-Mediated Kinase Cascades: Bifurcation of Nuclear Factor-κB and c-Jun N-terminal Kinase (JNK/SAPK) Pathways at TNF Receptor-associated Factor 2", <u>Proc. Natl. Acad. Sci. USA</u> 94:9792-9796 (1997)	
		Wallach, D., "Cell Death induction by TNF: A Matter of Self Control", <u>TIBS Trends in Biochemical Sciences</u> 22:107-109 (1997)	
		Woronicz, J.D. et al, "IκB Kinase-beta NF-κB Activation and Complex Formation with IκB Kinase-alpha and NIK", <u>Science</u> 278:866-869 (1997)	

Examiner
SignatureDate
Considered

2/5/06

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	
				Filing Date	Even Date Herewith
				First Named Inventor	David WALLACH
				Group Art Unit	1633
				Examiner Name	KINGMAN
				Attorney Docket Number	WALLACH=27A
Sheet	3	of	3		

[illegible]

Examiner Signature		Date Considered	2/5/06
-----------------------	---	--------------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.